Congenital nephrotic syndrome type 1 is a severe hereditary kidney disease, inherited in an autosomal recessive manner, caused by biallelic variants in the NPHS1 gene. This gene encodes nephrin, an essential protein of the podocyte slit diaphragm. Its alteration compromises the glomerular filtration barrier and causes massive protein loss through urine from birth or the first months of life.
Congenital nephrotic syndrome type 1
The NPHS1 gene provides instructions for making the protein nephrin, a key structural component of the slit diaphragm, the specialized junction that connects podocytes in the renal glomeruli. This structure is part of the kidney's filtration barrier and allows water and small molecules to pass into the urine, while retaining important plasma proteins such as albumin.
When pathogenic variants exist in NPHS1, nephrin is defective, unstable, or absent, making the glomerular barrier abnormally permeable. This results in massive proteinuria, hypoalbuminemia, edema, and a risk of infectious, thrombotic, and nutritional complications. The disease is inherited in an autosomal recessive pattern, meaning an affected person must inherit an altered copy of the gene from each parent. The classic form is also known as Finnish-type congenital nephrotic syndrome, due to its higher frequency in Finland from founder variants, although NPHS1 can cause disease in any population.
Symptoms
The onset is usually prenatal, neonatal, or during the first three months of life. The main signs are massive proteinuria, marked hypoalbuminemia, and generalized edema, which can be accompanied by low weight, growth retardation, recurrent infections due to loss of immunoglobulins, and episodes of thrombosis due to loss of anticoagulant proteins. Increased placental size, prematurity, secondary hypothyroidism, and difficulty maintaining an adequate nutritional state may also be observed. Without specialized management, the disease progresses to end-stage renal disease during childhood.
Disease management
Management is intensive and individualized, aimed at controlling protein loss, preventing complications, and preparing for kidney transplantation when necessary. It includes intravenous albumin infusions along with diuretics to control edema, nutritional support, protein and micronutrient supplementation, infection prevention, and monitoring of thrombotic risk. In some patients, antiproteinuric drugs may be used to try to reduce proteinuria. In severe cases, unilateral or bilateral nephrectomy, dialysis, and subsequent kidney transplantation may be required, which constitutes the definitive treatment to restore kidney function.
Genes analyzed
Bibliography
AbuMaziad AS, Abusaleh R, Bhati S. Congenital nephrotic syndrome. J Perinatol. 2021 Dec;41(12):2704-2712.
Boyer O, Schaefer F, Haffner D, et al. Management of congenital nephrotic syndrome: consensus recommendations of the ERKNet-ESPN Working Group. Nat Rev Nephrol. 2021 Apr;17(4):277-289.
Anderson S. Congenital Nephrotic Syndrome of the Finnish Type in a Dominican Newborn: An Overview and Case Report. Neonatal Netw. 2022 Mar 1;41(2):83-88.
